Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …

Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent
oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC) …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

As the major malignant tumors in the chest, non-small cell lung cancer (NSCLC) and
esophageal cancer (EC) bring huge health burden to human beings worldwide. Currently …

Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma
(LUAD). ALK is constitutively activated by gene fusion events between the ALK and other …

Precision medicine has helped identify several tumor molecular aberrations to be treated
with targeted therapies. These therapies showed substantial improvement in efficacy without …

Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …

Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades,
the management of non-small cell lung cancer (NSCLC) has undergone a significant …

Despite the initial benefit from tyrosine kinase inhibitors (TKI) targeting oncogenic ALK and
ROS1 gene fusions in non–small cell lung cancer, complete responses are rare and …

Objectives To compare the efficacy, safety and effects on quality of life of different ALK-
inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung …